Who does it first? The uptake of medical innovations in the performance of thrombolysis on ischemic stroke patients in Germany: a study based on hospital quality data

Implementation Science

Ute Karbach²  Gereon R Fink³  Helmar C Lehmann¹  Holger Pfaff²  Nadine Scholten² 

[1] Department of Neurology, University Hospital Cologne, Cologne, Germany;IMVR—Institute for Medical Sociology, Health Services Research, and Rehabilitation Science, University of Cologne, Cologne, Germany;Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Center Jülich, Jülich, Germany

关键词: Neurology;    Implementation;    Guideline;    Thrombolysis;    Ischemic stroke;   

Others  :  1139384
DOI  :  10.1186/s13012-014-0196-7

 received in 2014-06-06, accepted in 2014-12-18,  发布年份 2015

【 摘 要 】

Background

Since 2000, systemic thrombolysis has been the only approved curative and causal treatment for acute ischemic stroke. In 2009, the guidelines of the German Society for Neurology were updated and the therapeutic window for performing thrombolysis was extended. The implementation of new therapies is influenced by many factors. We analyzed the factors at the organizational level that influence the implementation of thrombolysis in stroke patients.

Methods

The data published by the majority of German hospitals in their structured quality reports was assessed. We calculated a regression model in order to measure the influence of hospital/department-level characteristics (e.g., teaching status, ownership, location, and number of hospital beds) on the implementation of thrombolysis in 2006 (this is the earliest point in time that can be analyzed on this data basis). In order to measure the effect of the guideline update in 2009 on the thrombolysis rate (TR) change between 2008 and 2010, we performed a Wilcoxon signed-rank test and utilized a regression model.

Results

In 2006, 61.5% of a total of 286 neurology departments performed systemic thrombolysis to treat ischemic strokes. The influencing factors for the use of systemic thrombolysis in 2006 were the existence of a stroke unit (+) and a hospital size of between 500 and 1,000 beds (−). A significant increase of the mean departmental TR (thrombolysis rate) from 6.7% to 9.2% between 2008 and 2010 was observed after the guideline update in 2009. For the departments performing thrombolysis in 2008 and 2010, our analysis could not show any additional influencing factors on a structural level that would explain the TR rise during the period 2008–2010.

Conclusions

Because ischemic stroke patients benefit from systemic thrombolysis, it is necessary to examine possible barriers at the organizational level that hinder the implementation. Our data shows that, organizational factors have an influence on the implementation of thrombolysis. However, the recent guideline update resulted in a TR rise that occurred at all hospitals, regardless of the measured structural conditions, as our analysis could not identify any structural factors that might have influenced the TR after the guideline update.

【 授权许可】

   
2015 Scholten et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al.: Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2095-128.
• [2]Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al.: Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2197-223.
• [3]Nimptsch U, Mansky T: Trends in acute inpatient stroke care in Germany—an observational study using administrative hospital data from 2005–2010. Dtsch Arztebl Int 2012, 109:885-92.
• [4]Zhang Y, Chapman A, Plested M, Jackson D, Purroy F: The incidence, prevalence, and mortality of stroke in France, Germany, Italy, Spain, the UK, and the US: a literature review. Stroke Res Treat 2012, 2012:436125.
• [5]Kaste M: Stroke: advances in thrombolysis. Lancet Neurol 2013, 12:2-4.
• [6]Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, et al.: Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 2013, 368:893-903.
• [7]Kidwell CS, Jahan R, Gornbein J, Alger JR, Nenov V, Ajani Z, et al.: A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med 2013, 368:914-23.
• [8]Ciccone A, Valvassori L, Nichelatti M, Sgoifo A, Ponzio M, Sterzi R, et al.: Endovascular treatment for acute ischemic stroke. N Engl J Med 2013, 368:904-13.
• [9]Jauch EC, Saver JL, Adams HP, Bruno A, Connors JJ, Demaerschalk BM, et al.: Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013, 44:870-947.
• [10]Zivin JA: Acute stroke therapy with tissue plasminogen activator (tPA) since it was approved by the U.S. Food and Drug Administration (FDA). Ann Neurol 2009, 66:6-10.
• [11]Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, et al.: Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007, 369:275-82.
• [12]Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al.: Thrombolysis with Alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008, 359:1317-29.
• [13]Wahlgren N, Ahmed N, Dávalos A, Hacke W, Millán M, Muir K, et al.: Thrombolysis with alteplase 3–4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008, 372:1303-9.
• [14]Deutsche Gesellschaft für Neurologie: Akuttherapie des ischämischen Schlaganfalls. [http://www.dgn.org/images/red_leitlinien/LL_2008/archiv/ll08kap_023.pdf]
• [15]The European Stroke Organization (ESO): Guidelines for Management of Ischemic Stroke update 2009. [http://www.congrex-switzerland.com/fileadmin/files/2013/eso-stroke/pdf/ESO_Guideline_Update_Jan_2009.pdf]
• [16]Zoppo D, Gregory J, Saver JL, Jauch EC, Adams HP: Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 2009, 40:2945-8.
• [17]Ahmed N, Wahlgren N, Grond M, Hennerici M, Lees KR, Mikulik R, et al.: Implementation and outcome of thrombolysis with alteplase 3–4.5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol 2010, 9:866-74.
• [18]Haines A, Kuruvilla S, Borchert M: Bridging the implementation gap between knowledge and action for health. Bull World Health Organ 2004, 82:724-31. discussion 732
• [19]Grol R: Successes and failures in the implementation of evidence-based guidelines for clinical practice. Med Care Res Rev 2001, 39:II1-92.
• [20]LaBresh KA: Hospital treatment of patients with ischemic stroke or transient ischemic attack using the “Get With The Guidelines” program. Arch Intern Med 2008, 168:411.
• [21]The Paul Coverdell Prototype Registries Writing Group: Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry Stroke 2005, 36:1232-40.
• [22]Klein KJ, Sorra JS: The challenge of innovation implementation. Acad Manag Rev 1996, 21:1055-80.
• [23]Chaudoir SR, Dugan AG, Barr CHI: Measuring factors affecting implementation of health innovations: a systematic review of structural, organizational, provider, patient, and innovation level measures. Implementation Sci 2013, 8:22. BioMed Central Full Text
• [24]Parsons HM, Begun JW, McGovern PM, Tuttle TM, Kuntz KM, Virnig BA: Hospital characteristics associated with maintenance or improvement of guideline-recommended lymph node evaluation for colon cancer. Med Care 2013, 51:60-7.
• [25]Lehrman WG, Elliott MN, Goldstein E, Beckett MK, Klein DJ, Giordano LA: Characteristics of hospitals demonstrating superior performance in patient experience and clinical process measures of care. Med Care Res Rev 2009, 67:38-55.
• [26]Brand CA, Barker AL, Morello RT, Vitale MR, Evans SM, Scott IA, et al.: A review of hospital characteristics associated with improved performance. Int J Qual Health Care 2012, 24:483-94.
• [27]Goldman LE, Dudley RA: United States rural hospital quality in the Hospital Compare database-accounting for hospital characteristics. Health Policy 2008, 87:112-27.
• [28]Baldwin L, MacLehose RF, Hart LG, Beaver SK, Every N, Chan L: Quality of care for acute myocardial infarction in rural and urban US hospitals. J Rural Health 2004, 20:99-108.
• [29]Meurer WJ, Majersik JJ, Frederiksen SM, Kade AM, Sandretto AM, Scott PA: Provider perceptions of barriers to the emergency use of tPA for acute ischemic stroke: a qualitative study. BMC Emerg Med 2011, 11:5. BioMed Central Full Text
• [30]Van Der Weijden T, Hooi JD, Grol R, Limburg M: A multidisciplinary guideline for the acute phase of stroke: barriers perceived by Dutch neurologists. J Eval Clin Pract 2004, 10:241-6.
• [31]Eriksson M, Jonsson F, Appelros P, Asberg KH, Norrving B, Stegmayr B, et al.: Dissemination of thrombolysis for acute ischemic stroke across a nation: experiences from the Swedish stroke register, 2003 to 2008. Stroke 2010, 41:1115-22.
• [32]Williams JM, Navin TJ, Jude MR, Levi CR: Recombinant tissue plasminogen activator (rt-PA) utilisation by rural clinicians in acute ischaemic stroke: an audit of current practice and clinical outcomes. Aust J Rural Health 2013, 21:203-7.
• [33]Rudd AG, Hoffman A, Grant R, Campbell JT, Lowe D: Stroke thrombolysis in England, Wales and Northern Ireland: how much do we do and how much do we need? J Neurol Neurosurg Psychiatr 2011, 82:14-9.
• [34]Adeoye O, Albright KC, Carr BG, Wolff C, Mullen MT, Abruzzo T, et al.: Geographic access to acute stroke care in the United States. Stroke 2014, 45:3019-24.
• [35]Kleindorfer D, Xu Y, Moomaw CJ, Khatri P, Adeoye O, Hornung R: US geographic distribution of rt-PA utilization by hospital for acute ischemic stroke. Stroke 2009, 40:3580-4.
• [36]Scholten N, Pfaff H, Lehmann H, Fink G, Karbach U: Thrombolyse des akuten Schlaganfalls—eine Deutschlandweite Analyse der regionalen versorgung. Fortschr Neurol Psychiatr 2013, 81:579-85.
• [37]Rogers EM: Diffusion of innovations. 5th edition. Free Press, New York; 2003.
• [38]Donnellan C, Sweetman S, Shelley E: Health professionals’ adherence to stroke clinical guidelines: a review of the literature. Health Policy 2013, 111:245-63.
• [39]Adeoye O, Hornung R, Khatri P, Kleindorfer D: Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years. Stroke 2011, 42:1952-5.
• [40]Asplund K, Glader E, Norrving B, Eriksson M: Effects of extending the time window of thrombolysis to 45 hours: observations in the Swedish stroke register (riks-stroke). Stroke 2011, 42:2492-7.
• [41]Paul CL, Levi CR, D'Este CA, Parsons MW, Bladin CF, Lindley RI, et al.: Thrombolysis Implementation in Stroke (TIPS): evaluating the effectiveness of a strategy to increase the adoption of best evidence practice—protocol for a cluster randomised controlled trial in acute stroke care. Implement Sci 2014, 9:38. BioMed Central Full Text
• [42]Weiner BJ, Belden CM, Bergmire DM, Johnston M: The meaning and measurement of implementation climate. Implementation Sci 2011, 6:78. BioMed Central Full Text
• [43]Weiner BJ: A theory of organizational readiness for change. Implementation Sci 2009, 4:67. BioMed Central Full Text
• [44]Shaw RJ, Kaufman MA, Bosworth HB, Weiner BJ, Zullig LL, Lee S, et al.: Organizational factors associated with readiness to implement and translate a primary care based telemedicine behavioral program to improve blood pressure control: the HTN-IMPROVE study. Implementation Sci 2013, 8:106. BioMed Central Full Text
• [45]Stecksen A, Lundman B, Eriksson M, Glader E, Asplund K: Implementing thrombolytic guidelines in stroke care: perceived facilitators and barriers. Qual Health Res 2013, 24:412-9.
• [46]Willems M, Schröder C, Post M, Van Der Weijden T, Visser-Meily A: Do knowledge brokers facilitate implementation of the stroke guideline in clinical practice? BMC Health Serv Res 2013, 13:434. BioMed Central Full Text
• [47]Godin G, Bélanger-Gravel A, Eccles M, Grimshaw J: Healthcare professionals’ intentions and behaviours: a systematic review of studies based on social cognitive theories. Implementation Sci 2008, 3:36. BioMed Central Full Text
• [48]Eissa A, Krass I, Bajorek BV: Barriers to the utilization of thrombolysis for acute ischaemic stroke. J Clin Pharm Ther 2012, 37:399-409.
• [49]Rossnagel K, Jungehülsing GJ, Nolte CH, Müller-Nordhorn J, Roll S, Wegscheider K, et al.: Out-of-hospital delays in patients with acute stroke. Ann Emerg Med 2004, 44:476-83.
• [50]Kruyt ND, Nederkoorn PJ, Dennis M, Leys D, Ringleb PA, Rudd AG, et al.: Door-to-needle time and the proportion of patients receiving intravenous thrombolysis in acute ischemic stroke: uniform interpretation and reporting. Stroke 2013, 44:3249-53.